Skip to content

Difference between anesthetic agents on liver damages after liver resection

Difference between anesthetic agents on liver damages after liver resection - Difference between anesthetic agents on liver damages after liver resection

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000034798
Enrollment
56
Registered
2018-12-12
Start date
2018-12-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic liver tumor

Interventions

sevoflurane arm permits only use of sevoflurane for maintenance of anesthesia. propoforl arm permits only use of propofol for maintenance of anesthesia.

Sponsors

National Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. elective resection for metastatic liver tumor( including suspect of metastatic tumor) from any primary tumor, and estimated number of these tumors is 5 or under, and resection size is under Couinaud 5 area. 2. preoperative values of aspartate aminotransferase and alanine aminotransferase are both under 100 IU/L. 3. NOT scheduling primary tumor resection and/of radiofrequency ablation at the same time as liver resection. 4.NOT scheduling biliary reconstruction at the same time as liver resection. 5. obtained written infromed consent from patient.

Exclusion criteria

Exclusion criteria: 1. known allergy of study drugs

Design outcomes

Primary

MeasureTime frame
max value of the aspartate aminotransferase during postoperative 3 days

Secondary

MeasureTime frame
max value of the alanine transaminase and total bilirubin during postoperative 3 days and postoperative complication defined by JCOG postoperative complication criteria according to Clavien-Dindo Classification grade 2 or more.

Countries

Japan

Contacts

Public ContactJunya Matsumi

National Cancer Center Hospital Department of Anesthesia and Intensive Care

jmatsumi@ncc.go.jp03-3542-2166

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026